BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 29955780)

  • 21. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
    Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
    Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
    Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
    World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.
    Kaushik D; Wang H; Michalek J; Liss MA; Liu Q; Jha RP; Svatek RS; Mansour AM
    Urology; 2019 Nov; 133():164-174. PubMed ID: 31401220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer.
    Pak S; You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Kim CS; Ahn H
    Clin Genitourin Cancer; 2019 Jun; 17(3):e420-e428. PubMed ID: 30713014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research.
    Bekelman JE; Handorf EA; Guzzo T; Evan Pollack C; Christodouleas J; Resnick MJ; Swisher-McClure S; Vaughn D; Ten Have T; Polsky D; Mitra N
    Value Health; 2013 Jun; 16(4):610-8. PubMed ID: 23796296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
    Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
    Lane G; Risk M; Fan Y; Krishna S; Konety B
    BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire.
    Chahal R; Sundaram SK; Iddenden R; Forman DF; Weston PM; Harrison SC
    Eur Urol; 2003 Mar; 43(3):246-57. PubMed ID: 12600427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
    Duivenvoorden WC; Daneshmand S; Canter D; Lotan Y; Black PC; Abdi H; van Rhijn BW; Fransen van de Putte EE; Zareba P; Koskinen I; Kassouf W; Traboulsi SL; Kukreja JE; Boström PJ; Shayegan B; Pinthus JH
    J Urol; 2016 Dec; 196(6):1627-1633. PubMed ID: 27312316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Alternatives to cystectomy].
    Niedworok C; Gratzke C
    Urologe A; 2015 Apr; 54(4):504-9. PubMed ID: 25895563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
    Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
    BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer.
    Miyata H; Osawa T; Abe T; Kikuchi H; Matsumoto R; Maruyama S; Nishioka K; Shimizu S; Hashimoto T; Shirato H; Shinohara N
    Jpn J Clin Oncol; 2020 May; 50(5):609-616. PubMed ID: 31955206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
    Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM
    JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
    Shipley WU; Kaufman DS; Zehr E; Heney NM; Lane SC; Thakral HK; Althausen AF; Zietman AL
    Urology; 2002 Jul; 60(1):62-7; discussion 67-8. PubMed ID: 12100923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
    Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
    Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.